Uwe Schlegel

Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA–09): a randomised, open-label, phase 3 trial

Ulrich Herrlinger, Theophilos Tzaridis, Frederic Mack et al. · The Lancet · 2019 · 556 citations · Full text

Hematological Malignancy, Neuro-oncology, Treatment Strategies +13

Phase I/IIa Study of Cilengitide and Temozolomide With Concomitant Radiotherapy Followed by Cilengitide and Temozolomide Maintenance Therapy in Patients With Newly Diagnosed Glioblastoma

Roger Stupp, Monika E. Hegi, Bart Neyns et al. · Journal of Clinical Oncology · 2010 · 439 citations · Full text

Primary Central Nervous System Lymphoma: Results of a Pilot and Phase II Study of Systemic and Intraventricular Chemotherapy With Deferred Radiotherapy

Hendrik Pels, Ingo G.H. Schmidt‐Wolf, Axel Glasmacher et al. · Journal of Clinical Oncology · 2003 · 420 citations

Plasma 24S-hydroxycholesterol (cerebrosterol) is increased in Alzheimer and vascular demented patients

Dieter Lütjohann, Andreas Papassotiropoulos, Ingemar Björkhem et al. · Journal of Lipid Research · 2000 · 377 citations · Full text

<i>MGMT</i> Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial

Michael Weller, Ghazaleh Tabatabai, Bärbel Kästner et al. · Clinical Cancer Research · 2015 · 311 citations · Full text